Background: Recent advances in outpatient parenteral antibiotic therapy (OPAT) have largely focused on adult practice, and there are few published data on the safety and effectiveness of pediatric OPAT (p-OPAT). Methods: During a 3-year period (2012 to 2015), data were prospectively collected on patients managed within the p-OPAT service at Southampton Children's Hospital, a tertiary pediatric hospital in the South of England. Results: A total of 130 p-OPAT episodes were managed during this period. The most frequently managed pathologies were bone and joint infections (44.6%), followed by ear, nose and throat (10.7%), respiratory (10.0%) and central nervous system (10.0%) infections. The most frequently used antimicrobial agent was ceftriaxone (n = 103; 79.2%). For the majority of p-OPAT episodes, antimicrobials were delivered in prefilled syringes (n = 109; 83.8%); 24-hour infusions administered by elastomeric devices were used less commonly (n = 16; 12.3%). The median duration of p-OPAT treatment was 9.2 days (interquartile range: 7.6-19.0 days). With regard to patient outcomes, 113 (86.9%) p-OPAT episodes resulted in cure and 12 (9.2%) in improvement; treatment failure occurred in 5 (3.9%) episodes. Intravenous catheter-related complications were rare. A total of 1683 bed days were saved over the 3-year period. Conclusions: Our data suggest that p-OPAT is safe and effective, with the potential to offer considerable savings for the healthcare economy through reduced length of inpatient stay.
BACKGROUND
Data from adult practice provide strong rationale for managing children and young people on intravenous antimicrobial therapy at home whenever possible. 1 Potential benefits include greater parent and patient satisfaction, enhanced psychologic well-being, earlier return to school or employment, reductions in healthcareassociated infections and substantial cost savings. Recent advances in outpatient parenteral antibiotic therapy (OPAT) have largely focused on adult practice, 2 and there are few published data on the impact of pediatric OPAT (p-OPAT) services. While it has been estimated that more than one in 1000 adults in the United States receive OPAT annually, 3 there are no reliable estimates regarding the use of OPAT in children.
In the United Kingdom, a joint collaboration between the British Society for Antimicrobial Chemotherapy and the British Paediatric Allergy, Immunity and Infection Group has proposed the formalization of clinical practice and governance of p-OPAT through good practice recommendations. 4 The aim of this initiative was to promote the delivery of safe and effective p-OPAT services to enhance patient experience, deliver healthcare closer to or at home, 5 reduce length of inpatient stay to deliver cost savings 6 and embed antimicrobial stewardship into clinical practice. 7 This prospective service evaluation aimed to describe the effectiveness and safety of p-OPAT treatment at a tertiary children's hospital in the South of England over a 3-year period.
METHODS
We prospectively collected data on patients managed by the p-OPAT service at Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust between July 2012 and June 2015. The hospital serves a regional population of approximately 500,000 children, has a total of 124 inpatients beds (excluding neonatal care) and has more than 9000 pediatric admissions per year. A p-OPAT service was introduced in July 2012, specifically designed to manage children with complex infections requiring prolonged intravenous antibiotic therapy of at least 5 days duration once discharged from the hospital. The p-OPAT team consisted of a pediatric infectious diseases consultant and a full-time p-OPAT nurse supported by a part time clinical/part time academic pediatric infectious diseases consultant and pediatric medical junior staff. These staff members not only delivered the p-OPAT service but also ran the pediatric infectious diseases service, antimicrobial stewardship service and the peripherally inserted central catheter (PICC) Line service. Patients suitable for p-OPAT were identified by the pediatric infectious diseases team on routine antibiotic stewardship ward rounds conducted 3 times a week or via direct referral from pediatric subspecialty teams.
Explicit eligibility criteria were used to assess p-OPAT suitability, with regards to clinical, social and caregiver factors. 4 If there were any concerns regarding potential patient/parent adherence or suitability of the home environment for p-OPAT, p-OPAT was not initiated. All p-OPAT patients included in this study were initially managed as inpatients by the referring team. The ability to administer antibiotics at home depended on the availability of local community pediatric nurses. In some cases, parents/caregivers administered their child's antibiotics at home after being trained appropriately. The choice of the antibiotic regimen was made by the p-OPAT consultant, taking the underlying pathology and the microbiologic test results into account. Before discharge home, parents or caregivers were provided with information on central line care by the p-OPAT nurse and taught about the recognition of potential complications by the p-OPAT nurse. Parents were able to directly contact the OPAT team 24 hours per day while being managed within the p-OPAT service. Outcomes were determined in all patients discharged from the p-OPAT service, defined as at the point when intravenous antibiotics were stopped. Treatment outcomes were classified according to previously published consensus definitions, 4 with minor modifications. Complications were identified either by parents or community-based nurses and communicated directly to the OPAT team or by the OPAT team at the weekly face-to-face clinic review. Concerning patient infection outcome, an p-OPAT episode was classified as either (a) cure: p-OPAT therapy was completed and/or an oral step-down was decided for a defined duration, with resolution of infection and no requirement for long-term antibiotic therapy; (b) improvement: completed p-OPAT therapy with partial resolution of infection requiring long-term oral step-down/escalation of antibiotics or cure requiring escalation of antibiotics (without admission); or (c) failure: progression or lack of clinical response despite p-OPAT, resulting in admission, surgical intervention or death. Concerning p-OPAT outcome, an p-OPAT episode was classified as either (a) success: p-OPAT therapy was completed without line complications or antimicrobial side effects requiring a change in antibiotics or line removal; (b) partial success: p-OPAT therapy was completed without readmission to hospital but required a change of antibiotics or line removal because of a line complication or antimicrobial side effects; or (c) failure: readmission or death because of line complications or antimicrobial side effects. Regarding weekly blood test monitoring, only abnormalities that required action (ie, stop/switch antimicrobials) were regarded as a drug complication.
Data Collection and Statistical Analyses
All data were collected prospectively in Excel (Microsoft; Redmond, Virginia, WA) as part of routine p-OPAT case management. The statistical analyses were performed, and figures were constructed with Prism V6 (GraphPad; La Jolla, CA).
Institutional Board Approval
The project was assessed by University Hospital Southampton NHS Foundation Trust to be a formal service evaluation under the UK Research Governance Framework (http://www.hradecisiontools.org.uk/research/glossary.html#S).
RESULTS
A total of 130 p-OPAT episodes in 123 patients were managed by the p-OPAT service over the 3-year period. The age distribution was as follows: 0 to 12 months (n = 8; 6.2%), 1 to 5 years of age (n = 50; 38.5%), 5 to 12 years (n = 43; 33.1%) and 12 to 18 years (n = 29; 22.3%). The male to female ratio was 1.2:1 (males: n = 66, females: n = 57). The most frequently managed pathologies were bone and joint infections (44.6%), followed by ear, nose and throat (10.7%), respiratory (10.0 %) and central nervous system (CNS) (10.0 %) infections (Fig. 1 ).
Causative Organisms
A causative pathogen was identified in 87 episodes (66.9%; 
Antimicrobial Agents Used
The most frequently used antimicrobial agent was ceftriaxone (n = 103; 79.2%). Other agents used were flucloxacillin (n = 6; 4.6%), piperacillin/tazobactam and teicoplanin (n = 6; 4.6%, each), daptomycin (n = 5; 3.8%) and ceftazidime combined with inhaled tobramycin (n = 4; 3.1%; Fig. 3 ).
Devices Used
For the majority of p-OPAT episodes, antimicrobials were delivered in prefilled syringes (n = 109; 83.8%). Twenty-four-hour infusions administered via an elastomeric device were used in 16 patients (12.3%) for the administration of flucloxacillin (n = 6), piperacillin/tazobactam (n = 6) and ceftazidime (n = 4). Daptomycin was dispensed as vials and reconstituted within the p-OPAT setting in 5 patients (3.9%).
Duration of Treatment
Overall, the median duration of p-OPAT treatment was 9.2 days (interquartile range: 7.6-19.0 days). The longest p-OPAT treatment duration was observed in cases with pyomyositis (n = 3, median 37 days), CNS infections (n = 13, median 18 days) and bacterial endocarditis (n = 6, median: 17 days), shown in Figure 4 . In most types of infections, p-OPAT treatment courses were longer than the duration of inpatient treatment before discharge home 
Inpatient Bed Days Saved
A total of 1683 bed days were saved over the period studied. These patients would otherwise have remained in hospital receiving intravenous antibiotics. The largest numbers of bed days saved were observed in the groups of patients with osteomyelitis and CNS infections, where p-OPAT treatment saved a total of 433 and 358 bed days, respectively. Other types of infections in which large numbers of bed days were saved included septic arthritis, bacterial endocarditis and respiratory infections (Fig. 5) .
Type of Intravenous Access
In the majority of p-OPAT episodes, patients received antimicrobial treatment via a PICC (n = 105; 80.8%). Ten patients (7.6%) had a preexisting tunneled central venous catheter in situ (8 oncology patients, 1 patient with chronic granulomatous disease, 1 patient with structural congenital cardiac anomalies). Peripheral cannulas were rarely used (n = 15, 11.5 %).
Service Structure
For the majority of p-OPAT episodes, intravenous antibiotics were administered at home by pediatric community nurses (n = 103; 79.2%) and at home by parents/carers in 3 episodes (2.3%). Twentyfour episodes (18.5%) involved administration on an ambulatory basis at the hospital local to the family, usually the original referring hospital, because of the lack of local community nursing provision.
Intravenous Catheter-related Complication
No catheter-related complications occurred in children with preexisting tunneled central venous catheters. Twelve (11.4%) PICC-related complications occurred during p-OPAT therapy. Mechanical complications (n = 9; 75%) comprised line migration/dislodgement (n = 5), line blockage (n = 3) and line fracture (n = 1). Infective complications (n = 3; 25%) comprised suspected 
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exit site infections (n = 2) and presumed central line-associated bloodstream infection (n = 1; not culture-proven). Three suspected drug-related complications (2.3%) were observed. One patient with osteomyelitis developed a generalized skin rash after 14 days of treatment with piperacillin/tazobactam. After treatment was discontinued the rash resolved. One patient with septic arthritis developed a generalized rash after 2 days of treatment with ceftriaxone. After switching to teicoplanin, the rash resolved. One patient with endocarditis developed a widespread rash, fever and neutropenia after 3 weeks of treatment with ceftriaxone. Delayed type IV hypersensitivity was diagnosed, and the rash resolved after the antimicrobial agent was changed.
Treatment Outcomes
One hundred and thirteen (86.9%) p-OPAT episodes resulted in cure and 12 (9.2%) in improvement, in terms of patient infection outcomes. Treatment failure occurred in 5 (3.9%) episodes. One patient with chronic granulomatous disease who had a persistent lower respiratory tract infection developed pyrexia after 14 days of treatment with piperacillin/tazobactam. After readmission, liposomal amphotericin B was added, which led to resolution of his fever within 2 days. The second patient had septic arthritis caused by Panton-Valentine leukocidin-producing S. aureus treated with ceftriaxone. Readmission was required for further surgical intervention. The three remaining patients were subsequently found to have noninfectious pathologies (inflammatory arthropathy, oesteosarcoma and acute lymphoblastic leukemia).
Most episodes of p-OPAT therapy were completed without any adverse events because of line complications or side effects of antimicrobial treatment (p-OPAT success, n = 114; 87.7%). In 13 episodes (10.0%), the p-OPAT course was complicated with an adverse event requiring a change in antibiotic therapy or line removal without the patient requiring readmission to hospital, mainly because of mechanical catheter-related complications and mild drug-related reactions such as minor skin rashes [p-OPAT partial success (Appendix 1)]. The p-OPAT outcome was considered failed in 3 cases (2.3%); 1 patient had to be readmitted for PICC replacement because of a blocked line (failed attempt to clear the line with urokinase), and 2 cases were readmitted with suspected catheter-related infections (p-OPAT failure). One of these 2 cases was a child being treated by the p-OPAT service for a central line infection.
DISCUSSION
These data are the first description of a formal p-OPAT cohort in Europe, demonstrating that p-OPAT delivered by a dedicated team allowed children with complex infections to be safely managed at home. Robust clinical governance, clear channels of communication and accurate outcome monitoring were an essential component of this work. 4 Readmission rates, rates of catheter-related complications and drug-related adverse events were very low. These rates were broadly similar to those described in other p-OPAT centers in the United States and Australia. 5, 8 Rates of PICC line complications were far lower than previously reported. 6, 7 Bone and joint infections made up the majority of cases within our service. Although there is little clinical trial evidence, clinicians are switching earlier from intravenous to oral antibiotics in osteoarticular infections. 9, 10 This is likely to result in such patients representing a smaller proportion of p-OPAT activity in the future. Respiratory cases made up only 10% of our p-OPAT cohort. Although pathologies such as infective exacerbations of cystic fibrosis appear amenable for management within a p-OPAT service, there is a lack of consensus about the safety of this approach. [11] [12] [13] Our experience is that an increasing number of subspecialist colleagues were prepared to consider the p-OPAT approach for their patients once the service was established, and robust safety and family satisfaction data were available.
P-OPAT clinicians need to remain mindful of their antimicrobial stewardship responsibilities and not prolong the duration of intravenous antimicrobial therapy unnecessarily. This is especially relevant given the ease of administering p-OPAT with minimal disruption to families. It is possible that waiting for a weekly review before stopping antibiotics may have unnecessarily prolonged the duration of intravenous antibiotics in some of our patients. The mean duration of p-OPAT therapy in our cohort was 9.2 days. This is similar to that reported by other p-OPAT centers. 5, 8 As there is little high-quality evidence currently supporting the optimal timing of switching from intravenous to oral antibiotics, comparing duration of antibiotic therapy between p-OPAT centers for specific pathologies may provide useful information in future to guide clinical practice where formal clinical trials are not feasible or unlikely to provide information for some time. 14 Ceftriaxone was by far the most commonly used antibiotic because of its once-per-day ease of administration and excellent side-effect profile. Higher dose (≥80 mg/kg/day) ceftriaxone has been used widely for once daily dosing in the United Kingdom for pediatric infections, including those caused mostly by S. aureus such as bone and joint infections, with apparently low treatment failure rates in or out of hospital. 15 Although p-OPAT infection outcomes were extremely good using this approach, clinicians are coming under increasing pressure to use narrow-spectrum antibiotics where possible to reduce the evolution of antimicrobial resistance. 16 However, no patients within our cohort developed clinical Clostridium difficile infection or infection with vancomycin-resistant Enterococcus. Balancing the risks and benefits of using a welltolerated once-daily antibiotic versus a narrow-spectrum agent requiring multiple daily dosing is a genuine challenge for clinicians. However, continuous infusion via elastomeric devices represents a potential alternative that can facilitate the administration of certain antibiotic agents that require multiple daily doses. 17 Administration of antibiotics by parents/caregivers made up an extremely small proportion of p-OPAT episodes (2.3%). With increasing confidence in the safety of p-OPAT, it is likely that this proportion will increase significantly. Administration using selfinfusing elastomeric devices administered via a PICC line occurred in 16 p-OPAT episodes (12.3%). Informal feedback suggested that elastomerics are preferred to syringe drivers because of ease of use.
One of the limitations of this study is that it did not include children being ambulated on short courses of intravenous antibiotics (ie, <5 days). Such patients make up the majority of children receiving intravenous antibiotics and are likely to pose different challenges to the patients described within our cohort. At present, such patients are not managed within the p-OPAT service. Our data suggest that p-OPAT is safe and effective. Within a dedicated, well-managed p-OPAT service, both treatment failures and complications are comparatively rare. Importantly, p-OPAT has the potential to offer considerable savings for the healthcare economy through reduced length of inpatient stay and free up precious bed spaces at a time when many healthcare systems in Europe and North America are under pressure. 18, 19 
